Risk Factors for Treatment-Related Death Associated with Chemotherapy and Thoracic Radiotherapy for Lung Cancer

Yuko Minami-Shimmyo(National Cancer Center Hospital East), Tomohide Tamura(St. Luke's International Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Seiichiro Yamamoto(National Cancer Centre Japan), Ikuo Sekine(University of Tsukuba), Hiroshi Nokihara(Tokushima University Hospital), Yuichiro Ohe(National Cancer Center), Kaoru Kubota(Nippon Medical School Hospital), Hidehito Horinouchi(Tokyo National Hospital), Noboru Yamamoto(Tokyo National Hospital)
Journal of Thoracic Oncology
December 2, 2011
10.1097/jto.0b013e31823c4c07
Cited by 60

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
|Annals of Oncology|2020|443